Clinical trials: Docetaxel, completed
Prostate Neoplasms, Prostate Cancer
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the maximum safe dose of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- mCRPC (NCT01400555)
- Testing
- Cohort 4, Cohort 3, Cohort 2
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cougar Biotechnology, Inc.
Breast Cancer
Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".
- Trial name
- NCT00600249
- Testing
- Cetuximab, Docetaxel
- Where
- 6 sites in France
- Volunteers
- 35 people
- Sponsor
- Centre Jean Perrin
Non-Small Cell Lung Cancer
Study to Evaluate SID 530 Compared to Taxotere
This is a multi-center, randomized, blinded, two-period, two-sequence, crossover study, with a minimum 3-week washout period between treatments.The study is designed to evaluate the bioequivalence of SID530 to Taxotere.
- Trial name
- NCT00931008
- Testing
- SID530, Taxotere
- Where
- 4 sites in United States, India
- Volunteers
- 42 people
- Sponsor
- SK Chemicals Co., Ltd.
Breast Cancer
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no…
- Trial name
- NCT03264547
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 446 people
- Sponsor
- Japan Breast Cancer Research Group
Non Small Cell Lung Cancer
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
- Trial name
- NCT00890825
- Testing
- AZD6244, docetaxel
- Where
- 63 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Breast Cancer, Elderly
Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients
The goal is to study the biology of aging in breast cancer patients, and to study the impact of chemotherapy on aging related blood biomarkers.
- Trial name
- EBS (NCT00849758)
- Where
- 2 sites in Belgium
- Volunteers
- 110 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
This Phase III, multicenter, open-label, randomized, controlled study is designed to evaluate the efficacy and safety of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab compared with docetaxel in participants…
- Trial name
- IMpower210 (NCT02813785)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel
- Where
- 38 sites in China, Malaysia and 3 more
- Volunteers
- 565 people
- Sponsor
- Hoffmann-La Roche
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
Unspecified Adult Solid Tumor, Protocol Specific
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of giving 1-methyl-d-tryptophan and docetaxel together in treating patients with metastatic solid tumors.
- Trial name
- NCT01191216
- Testing
- 1-methyl-d-tryptophan, docetaxel, diagnostic laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Molecularly Tailored Therapy for Pancreas Cancer
Patient therapy is tailored according to the molecular profile of the patient's tumor.
- Trial name
- NCT01888978
- Testing
- Gem-OX, Gem-5FU, Gem-Tax
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Head and Neck Cancer
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited.
- Trial name
- NCT00193284
- Testing
- Gefitinib, Docetaxel, Carboplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Breast Cancer Female
Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
The purpose of this study is to adjust the amount of docetaxel participants receive based on the level of docetaxel measured in their blood. This method of dose adjustment is called pharmacokinetic (PK)-adjusted docetaxel.
- Trial name
- NCT02502864
- Testing
- Standard of Care: Docetaxel, Standard of Care: Cyclophosphamide, Function Assessment of Cancer Therapy (FACT) Surveys
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Primary Breast Cancer
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
We aimed to evaluate the noninferiority of short-term anthracycline-free chemotherapy (TC, six cycles of docetaxel and cyclophosphamide) or short-term anthracycline-based chemotherapy (CEF-T, three cycles of…
- Trial name
- NCT01314833
- Testing
- Docetaxel Cyclophosphamide, Cyclophosphamide Fluorouracil Epirubicin Docetaxel, Epirubicin Cyclophosphamide Paclitaxel
- Where
- China
- Volunteers
- 1,570 people
- Sponsor
- Fudan University
Breast Cancer
PET in Breast Cancer Receiving Neoadjuvant Chemotherapy
Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer.
- Trial name
- DA-PET (NCT01396655)
- Testing
- docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
- Volunteers
- 78 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Non-Small-Cell Lung
Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer(NSCLC) is the leading cause of death in Korean men after stomach cancer. Surgical resection plays a main role for curative treatment.
- Trial name
- NCT00326378
- Testing
- consolidation chemotherapy with Docetaxel plus cisplatin, CCRT arm without consolidation chemotherapy
- Where
- South Korea
- Volunteers
- 434 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer
Phase II study of neoadjuvant chemotherapy with Doxorubicin followed by Docetaxel-Cisplatin in locally advanced breast cancer
- Trial name
- NCT00538525
- Testing
- Doxorubicin, Docetaxel, Cisplatin
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Prostate Cancer
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
Purpose: The purpose of this clinical trial is to look at the chemotherapy combination of docetaxel and capecitabine in the treatment of newly diagnosed or locally advanced prostate cancer, and to determine if this treatment is…
- Trial name
- NCT00151047
- Testing
- Capecitabine, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Gastric Cancer
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
Because well-designed, randomized, controlled clinical trials are lacking in patients with advanced gastric cancer (AGC), and because randomly allocating patients to treatments that do not accord with their preferences may…
- Trial name
- NCT00821990
- Testing
- Chemotherapy, Best supportive care
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you…
- Trial name
- NCT00051974
- Testing
- VELCADE™ (bortezomib) for Injection (formerly PS-341)
- Where
- 20 sites in United States
- Volunteers
- 155 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostatic Neoplasms
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see what effects (good and bad) it has on you and on…
- Trial name
- NCT00064610
- Testing
- VELCADE TM (bortezomib) for Injection
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.